SEARCH:   Advanced

Blood, 1 February 2008, Vol. 111, No. 3, pp. 1504-1511. Prepublished online as a Blood First Edition Paper on November 9, 2007; DOI 10.1182/blood-2007-03-080507. This Article Full Text (PDF) Supplemental Methods and Figure All Versions of this Article: blood-2007-03-080507v1 111/3/1504    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Franki, S. N Articles by Timmerman, J. M Search for Related Content PubMed PubMed Citation Articles by Franki, S. N Articles by Timmerman, J. M Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 19, 2007 Accepted November 2, 2007 Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B cell lymphoma in vivo Suzanne N Franki, Kristopher K Steward, David J Betting, Kamran Kafi, Reiko E Yamada, and John M Timmerman* Division of Hematology & Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, United States Molecular Biology Institute, University of California Los Angeles, Los Angeles, CA, United States * Corresponding author; email: jtimmerman{at}mednet.ucla.edu. The in vitro priming of tumor-specific T cells by dendritic cells (DCs) phagocytosing killed tumor cells can be augmented in the presence of anti-tumor monoclonal antibody (mAb). We investigated whether DCs phagocytosing killed lymphoma cells coated with tumor-specific antibody could elicit anti-tumor immunity in vivo. Irradiated murine 38C13 lymphoma cells were co-cultured with bone marrow-derived DCs in the presence or absence of tumor-specific mAb. Mice vaccinated with DCs co-cultured with mAb-coated tumor cells were protected from tumor challenge (60% long-term survival), whereas DCs loaded with tumor cells alone were much less effective. The opsonized whole tumor cell-DC vaccine elicited significantly better tumor protection than a traditional lymphoma idiotype (Id) protein vaccine, and in combination with chemotherapy could eradicate pre-existing tumor. Moreover, the DC vaccine protected animals from both wild-type and Id-negative variant tumor cells, indicating that Id is not a major target of the induced tumor immunity. Protection was critically-dependent upon CD8+ T cells, with lesser contribution by CD4+ T cells. Importantly, opsonized whole tumor cell-DC vaccination did not result in tissue-specific autoimmunity. Since opsonized whole tumor cell-DC and Id vaccines appear to target distinct tumor antigens, optimal anti-lymphoma immunity might be achieved by combining these approaches. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. J. Betting, K. Kafi, A. Abdollahi-Fard, S. A. Hurvitz, and J. M. Timmerman Sulfhydryl-Based Tumor Antigen-Carrier Protein Conjugates Stimulate Superior Antitumor Immunity against B Cell Lymphomas J. Immunol., September 15, 2008; 181(6): 4131 - 4140. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020